Increased procoagulant activity of red blood cells in the presence of cisplatin  

作　　者：LV Cheng-fang YU Hong-juan HOU Jin-xiao ZHOU Jin 

机构地区：[1]Department of Hematology, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China

出　　处：《Chinese Medical Journal》2008年第18期1775-1780,共6页中华医学杂志（英文版）

基　　金：This study was supported by the grants from the Emphasized Program from the Natural Science Foundation of Heilongjiang Province （No. ZJY0502）, the International Cooperation Foundation （No. WH05C01）, the National Traditional Chinese Medicine Bureau Research Foundation （No. 0607LP15）, and the Foundation for Post-graduate of Heilongjiang Province （No. YJSCX2007 0325HLJ）.

摘　　要：Background Cisplatin based chemotherapy is a well recognized risk factor for coagulation disorders and thrombosis. The pathophysiological mechanisms by which cisplatin promote thrombosis are not well understood. Methods Red blood cells （RBCs） were separated from peripheral blood of patients with breast cancer （n=10） and healthy adults （n=6） and treated with cisplatin. Coagulation time of RBCs was assessed by one step recalcification time and the productions of thrombin, intrinsic and extrinsic factor Xa were measured in the presence or absence of various concentrations of lactadherin. Exposed phosphatidylserine was stained with lactadherin and observed by confocal microscopy and flow cytometry. Results Neither fresh RBCs nor RBCs treated without cisplatin had potent procoagulant activity. Cisplatin treatment increased procoagulant activity of RBCs in a cell number- and concentration-dependent manner. Exposed phosphatidylserine was stained with lactadherin and after cisplatin treatment, strong fluorescence was revealed by confocal microscopy. Lactadherin bound RBCs from patients with breast cancer increased from （1.9＋0.5）% on control RBCs to （68.0±3.5）% on RBCs treated with 10umol/L cisplatin for 24 hours. Conclusions Cisplatin treatment increases procoagulant activity of RBCs, which have a strong association with exposure of phosphatidylserine. The increased procoagulant activity may contribute to the pathogenesis of thrombophilia during cisplatin based chemotherapy in breast cancer patients.Background Cisplatin based chemotherapy is a well recognized risk factor for coagulation disorders and thrombosis. The pathophysiological mechanisms by which cisplatin promote thrombosis are not well understood. Methods Red blood cells （RBCs） were separated from peripheral blood of patients with breast cancer （n=10） and healthy adults （n=6） and treated with cisplatin. Coagulation time of RBCs was assessed by one step recalcification time and the productions of thrombin, intrinsic and extrinsic factor Xa were measured in the presence or absence of various concentrations of lactadherin. Exposed phosphatidylserine was stained with lactadherin and observed by confocal microscopy and flow cytometry. Results Neither fresh RBCs nor RBCs treated without cisplatin had potent procoagulant activity. Cisplatin treatment increased procoagulant activity of RBCs in a cell number- and concentration-dependent manner. Exposed phosphatidylserine was stained with lactadherin and after cisplatin treatment, strong fluorescence was revealed by confocal microscopy. Lactadherin bound RBCs from patients with breast cancer increased from （1.9＋0.5）% on control RBCs to （68.0±3.5）% on RBCs treated with 10umol/L cisplatin for 24 hours. Conclusions Cisplatin treatment increases procoagulant activity of RBCs, which have a strong association with exposure of phosphatidylserine. The increased procoagulant activity may contribute to the pathogenesis of thrombophilia during cisplatin based chemotherapy in breast cancer patients.

关 键 词：procoagulant activity red blood cell PHOSPHATIDYLSERINE CISPLATIN LACTADHERIN 

分 类 号：R973[医药卫生—药品]